HRS 2016 roundup: Leadless pacers at the fore

Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), aiming to distinguish their respective leadless pacemaker offerings, presented new data last week in San Francisco at the Heart Rhythm Society’s annual meeting. St. Jude said a subset of data from the Leadless II trial showed that its Nanostim device was was successfully retrieved in 14 patients up to 3.2 years after implantation, with no serious adverse events. “We’ve now shown that for patients requiring device upgrades or new leadless pacing options, late retrievability – even up to 3 years – is possible with the Nanostim leadless pacemaker,” lead investigator Dr. Vivek Reddy, of New York City’s Mount Sinai Hospital, said in prepared remarks. Leadless II also compared a 718-patient Nanostim-implanted group with a cohort of 10,521 patients implanted with traditional transvenous pacers, using data from Truven MarketScan tracking of healthcare claims and Medicare supplemental insurance encounters. Acute complications occurred in 5.8% of the Nanostim group, compared with 12.7% of patients in the traditional pacer arm. Mid-term complications in the 1st 2 years after implantation were 0.6% for the Nanostim arm and 5.4% for the TVP arm, the Leadless II data showed. “Real-world claims data indicate higher-than-previously-reported rates of TVP complications with clear advantages for LCPs among infectious and lead-related events. LCPs and TVPs had similar rates of dislodgement an...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Clinical Trials Boston Scientific Cardiac Rhythm Management HRS 2016 Medtronic St. Jude Medical Source Type: news